VPOIS - Publicly Accessible Professional Information Service
IBSA PHARMA s.r.o., as the authorized representative of the marketing authorization holder, which is the company IBSA Slovakia s.r.o. (with registered office: Mýtna 42, 811 07 Bratislava, Slovakia), established pursuant to Act No. 378/2007 Coll. on medicinal products as amended by the Publicly Accessible Professional Information Service (VPOIS). In the list below, after clicking on the name of the medicinal product, you will be redirected to the Czech website of the State Institute for Drug Control (SÚKL). Here after changing the language into English and after clicking on the name of a specific medicinal product, you will get more information. In the Product Information tab, you will find the Summary of Product Characteristics (SmPC) and Patient´s Information Leaflet (PIL). You can find information on the current availability of medicinal products in the Availability tab.
All other available information about medicinal products distributed by IBSA PHARMA s.r.o. can be found on the website of the State Institute for Drug Control (SÚKL) in the Medicinal Products Database HERE
BETESIL
Marketed in the Czech republic: NO
CONDROSULF 400MG
Marketed in the Czech republic: YES
CONDROSULF 800MG
Marketed in the Czech republic: YES
FLECTOR RAPIDCAPS
Marketed in the Czech republic: YES
FLALGO
Marketed in the Czech republic: YES
FLECTOR GEL
Marketed in the Czech republic: YES
FLECTOR GRANULATE
Marketed in the Czech republic: YES
FLECTOR MEDICAL PLASTER
Marketed in the Czech republic: YES
FOSTIMON
Marketed in the Czech republic: YES
IALUGEN PLUS IMPREGNATED GAUZR
Marketed in the Czech republic: YES
IALUGEN PLUS CREAM
Marketed in the Czech republic: YES
MERIOFERT
Marketed in the Czech republic: NO
MERIOFERT SET
Marketed in the Czech republic: YES
PROLUTEX
Marketed in the Czech republic: YES
SOLMUCOL GRANULATE
Marketed in the Czech republic: YES
SOLMUCOL LOZENGES
Marketed in the Czech republic: YES
SYNOTIREX
Marketed in the Czech republic: NO
SYNTROXINE
Marketed in the Czech republic: YES
ZIVAFERT
Marketed in the Czech republic: YES
If you have any problem finding an information, please use the following contacts or the contact form.
IBSA PHARMA s.r.o.,
Senovážné náměstí 1463/5
Nové Město
110 00 Praha 1 Czechia
Phone: +420 221 111 500
Adverse event reporting
If you have experienced an adverse effect when using any medicinal product distributed by IBSA PHARMA s.r.o., please report it to one of the contacts listed below:
Phone: +420 221 111 500
E-mail: hlaseni.cz@ibsagroup.com
You can also report side effects directly to the State Institute for Drug Control:
Státní ústav pro kontrolu léčiv
Šrobárova 48
100 41 Praha 10 Czechia